Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of MEDI4736 (Durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated ANTIPD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study)
See Screening Protocol LUNGMAP
Effective November 6th, 2019 at 2:00 pm Pacific Time, Cohort 1, the acquired resistance cohort of substudy S1400F will permanently close to accrual. Please note that Cohort 2, the primary resistance cohort, has been reactivated and is open to accrual.
S1400F Cohort 2, the primary resistance cohort, will be permanently closed to accrual effective March 24, 2020 at 12:00 p.m. Pacific Time, due to study feasibility.